Objective: To evaluate the role of WF10 immunotherapy in reducing oro-pharyngeal complications in head and neck cancer chemoradiotherapy.
Material and Method: Thirteen patients were enrolled and assigned either to WF10- (n = 6) or control group (n = 7). After completion of their initial (neoadjuvant) chemotherapy, patients received WF10 intravenous infusions at 0.5 mL/kg body weight/day for five consecutive days and repeated every 3 weeks, concomitantly to standard radiotherapy (6,600-7,500 cGy, 200 cGy/day). Control patients received radiotherapy alone.
Results: Patients in the WF10-group had a lower incidence of oro-pharyngeal complications grade >2, including oral mucositis (1 vs. 5), dysphagia (2 vs. 7), oral pain (3 vs. 5), taste alteration (4 vs. 6) and weight loss (2 vs. 4). The statistical significances were achieved for the parameters of oral mucositis (p = 0.048) and dysphagia (p = 0.009).
Conclusion: WF10 appears to reduce severity of oro-pharyngeal complications associated with standard chemoradiotherapy for head and neck cancer.

Keywords: Tetrachlorodecaoxygen (TCDO iv, WF10), Chemotherapy, Radiotherapy, Mucositis, Head and Neck Cancer